What Is New in Cutaneous T Cell Lymphoma?
Sarah MorgenrothAndrea RoggoLaura PawlikReinhard DummerEgle RamelytePublished in: Current oncology reports (2023)
Cohort studies indicate imaging may be necessary in early-stage CTCL. Risk factors for progression of CTCL have been identified. Interactions between malignant cells and the tumor microenvironment (TME) and the skin microbiome advance the understanding of pathogenesis and tumor cell dissemination. Studies support a hypothesis of circulating malignant tumor cells. MicroRNA (miR) influence tumor progression and prognosis; the IL22-STAT3-CCL20 cascade may be a novel target. IL-4, IL-5, and IL-31 cytokines are relevant for pruritus and could be targets for therapeutic interventions. Systemic therapies, such as JAK inhibitors, targeted antibodies, and checkpoint inhibitors, show promise in advanced stages. Allogenic hematopoietic stem cell transplantation provides a potential curative option for patients. Further investigations of prognosis and translational research are necessary to improve stratification of patients for treatment.
Keyphrases
- end stage renal disease
- early stage
- newly diagnosed
- prognostic factors
- ejection fraction
- chronic kidney disease
- acute myeloid leukemia
- stem cells
- dna damage
- squamous cell carcinoma
- patient reported outcomes
- poor prognosis
- radiation therapy
- cell therapy
- cell cycle
- risk assessment
- machine learning
- artificial intelligence
- signaling pathway
- fluorescence imaging
- rectal cancer
- neoadjuvant chemotherapy
- cell cycle arrest
- sentinel lymph node